Table 2.

Distribution of SNPs and likelihood ratio test P values from Cox proportional hazards models of prostate cancer mortality among 1,252 cases

Geners numberLocationVariationMinor allele frequencyLRT P value*
Multivariate model 1Multivariate model 2
COX-2rs2745557202C>T0.170.930.89
rs52756,365T>C0.350.240.48
rs46482763,935T>C0.110.910.97
rs6894708,365C>T0.030.790.97
rs204323,100T>G0.140.760.94
IL-1RNrs8789722,118A>C0.260.480.78
rs3159348,111T>C0.190.980.99
rs308726310,173G>A0.090.960.70
rs31595114,992C>G0.330.090.09
IL-6rs14743481,027G>C0.490.700.78
rs20698453,268G>A0.480.150.29
rs1800795−237G>C0.490.440.79
rs1800796−636G>C0.040.800.64
rs1800797−661G>A0.490.620.89
IL-10rs1800871−853C>T0.260.660.46
rs1800872−627C>A0.270.660.46
rs30245092,483T>C0.070.890.94
rs30245055,876C>T0.120.660.29
rs1800896−1,117A>G0.460.800.83
rs15542861,547C>T0.220.780.55
IRAK1rs10597021,071 (F196S)C>T0.120.860.79
rs70617894,788T>C0.180.980.99
rs10597036,434 (S532L)T>C0.130.800.87
rs30278789,373T>G0.180.990.99
IRAK4rs1057190−13,656T>C0.110.360.40
rs4251431−7,225G>T0.090.700.92
rs4251571−2,001A>G0.020.430.15
rs4251459652T>C0.110.360.44
rs42514877,987G>C0.020.580.44
rs425154518,380 (A428G)G>A0.100.710.87
rs425155920,791A>G0.440.660.58
MIC-1rs1058587Exon2 +2,423C>G0.280.950.99
rs1059519Exon1 +25C>G0.290.140.53
rs1059369Exon1 +142A>T0.270.300.41
rs1227732IVS1 +1,809G>T0.160.002§0.009
MyD88rs4988453−938C>A0.060.390.19
TIRAPrs6460059,537T>C0.370.710.79
rs817737614,115T>G0.240.960.80
rs1229046817,678G>A0.050.710.99
TLR1rs5743551−7,202A>G0.230.020.03
rs5743556−6,399T>C0.150.210.35
N/A−2,299T>C0.180.820.98
rs5743604−833T>C0.300.040.06
rs5743611238G>C0.110.980.89
rs46246632,576A>G0.040.960.99
TLR2rs3804099596T>C0.430.580.61
rs38041001,349T>C0.060.260.38
TLR3rs3775296−7C>A0.180.780.94
rs57433132,593C>T0.180.820.92
rs37752916,301C>T0.300.920.44
rs5743303−8,921A>T0.170.750.94
rs57433058,441T>A0.330.800.80
TLR4rs11536889−11,380G>C0.120.840.74
rs10759932−1,607T>C0.150.990.86
rs2149356IVS3−468G>T0.300.640.56
rs49867908,551A>G0.050.870.99
rs1927914−2,026A>G0.330.720.88
rs107599333,622A>C0.050.990.96
rs50307219,615G>A0.010.940.86
rs115368713,748A>C0.020.920.97
rs787378412,185G>C0.140.960.97
rs1153689117,050T>C0.140.860.99
TLR5n/a−27,694C>T0.480.390.17
rs2241096−23,799C>T0.120.980.92
rs20724931,774A>G0.150.990.94
rs57441741,845T>C0.480.730.56
rs10539542,533A>G0.080.750.71
TLR6rs5743788−2,113C>G0.500.090.16
rs5743795−1,401G>A0.180.160.31
rs5743806−673G>C0.320.090.11
rs5743810744C>T0.400.170.30
rs57438151,279T>C0.020.710.93
TLR7rs2302267−120T>G0.060.780.87
rs1790194,271C>A0.230.990.95
rs1790168,744G>C0.410.320.58
rs162023312,381C>T0.100.100.20
rs17900817,961A>T0.250.950.84
TLR8rs1548731−558C>T0.260.620.99
rs48308063,467C>T0.390.840.55
rs57440686,553C>T0.160.830.97
rs57440809,299C>T0.360.990.99
rs574408812,059G>C0.160.830.98
TLR9rs187084−1,486T>C0.440.0090.05
TLR10rs11466617−3,260T>C0.160.120.12
rs11466640−1,692C>T0.170.270.41
rs4274855−260G>A0.170.320.52
rs11096957720 (N241H)A>C0.370.040.06
rs110969551,104 (1369L)A>C0.360.090.18
rs114666571,417 (1473T)T>C0.020.360.22
rs41290092,332 (1775V)A>G0.170.250.34
TNF-αrs1799724G1−857C>T0.070.990.99
rs1800750G1−376G>A0.010.720.81
rs3093662G1-IVS1 −122A>G0.040.960.87
rs361525G2−238G>A0.030.990.99
rs3093664G2-IVS3 +51A>G0.070.560.79
rs3093665G3-EX4 +499A>C0.010.440.29
rs1800629TNFa −308G>A0.180.110.12
rs769178G4-3′ +1402G>T0.070.990.99
rs1800630G5−863C>A0.170.940.76
  • NOTE: HRs (99% CIs) are shown in Supplementary Table 1.

  • Abbreviations: LRT, likelihood ratio test.

  • * From a Cox proportional hazards model of the codominant genotype when the frequency of rare heterozygotes >0.05 and from a dominant genotype otherwise.

  • Controlling for age and geographic location.

  • Controlling for age, geographic location, and indicator variables for curative and hormonal treatment.

  • § HR (99% CI) for GT/TT versus GG: 0.54 (0.34, 0.87).

  • HR (99% CI) for TC versus TT: 1.57 (1.02, 2.41); CC versus TT: 1.02 (0.57, 1.84).